JP2009523806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523806A5 JP2009523806A5 JP2008551369A JP2008551369A JP2009523806A5 JP 2009523806 A5 JP2009523806 A5 JP 2009523806A5 JP 2008551369 A JP2008551369 A JP 2008551369A JP 2008551369 A JP2008551369 A JP 2008551369A JP 2009523806 A5 JP2009523806 A5 JP 2009523806A5
- Authority
- JP
- Japan
- Prior art keywords
- ray diffraction
- diffraction pattern
- benzazepine
- fluorobenzoyl
- methoxybenzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 claims 158
- -1 2-Chloro-5-fluorobenzoyl Chemical group 0.000 claims 92
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 79
- 238000002441 X-ray diffraction Methods 0.000 claims 50
- 238000000634 powder X-ray diffraction Methods 0.000 claims 50
- 206010019280 Heart failures Diseases 0.000 claims 20
- 241000124008 Mammalia Species 0.000 claims 20
- 206010047163 Vasospasm Diseases 0.000 claims 19
- 238000000034 method Methods 0.000 claims 13
- 239000007787 solid Substances 0.000 claims 13
- 239000002904 solvent Substances 0.000 claims 11
- 208000019901 Anxiety disease Diseases 0.000 claims 10
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 10
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 10
- 208000005171 Dysmenorrhea Diseases 0.000 claims 10
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 10
- 206010016654 Fibrosis Diseases 0.000 claims 10
- 206010016807 Fluid retention Diseases 0.000 claims 10
- 206010020772 Hypertension Diseases 0.000 claims 10
- 206010021036 Hyponatraemia Diseases 0.000 claims 10
- 208000027601 Inner ear disease Diseases 0.000 claims 10
- 208000001738 Nervous System Trauma Diseases 0.000 claims 10
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 10
- 206010030113 Oedema Diseases 0.000 claims 10
- 208000001647 Renal Insufficiency Diseases 0.000 claims 10
- 208000006011 Stroke Diseases 0.000 claims 10
- 208000007536 Thrombosis Diseases 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 10
- 230000036506 anxiety Effects 0.000 claims 10
- 210000003169 central nervous system Anatomy 0.000 claims 10
- 230000007882 cirrhosis Effects 0.000 claims 10
- 208000019425 cirrhosis of liver Diseases 0.000 claims 10
- 208000033679 diabetic kidney disease Diseases 0.000 claims 10
- 208000028867 ischemia Diseases 0.000 claims 10
- 201000006370 kidney failure Diseases 0.000 claims 10
- 208000028412 nervous system injury Diseases 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 10
- 206010001488 Aggression Diseases 0.000 claims 9
- 201000008383 nephritis Diseases 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 208000011580 syndromic disease Diseases 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 8
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 4
- 238000001704 evaporation Methods 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 230000008018 melting Effects 0.000 claims 3
- 238000002844 melting Methods 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- GZDFNOOZOGEXDS-UHFFFAOYSA-N 4H-1-benzazepine Chemical compound N=1C=CCC=C2C=1C=CC=C2 GZDFNOOZOGEXDS-UHFFFAOYSA-N 0.000 claims 1
- 206010065673 Nephritic syndrome Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76042706P | 2006-01-20 | 2006-01-20 | |
| US82378406P | 2006-08-29 | 2006-08-29 | |
| PCT/US2007/001291 WO2007084591A2 (en) | 2006-01-20 | 2007-01-18 | Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523806A JP2009523806A (ja) | 2009-06-25 |
| JP2009523806A5 true JP2009523806A5 (enExample) | 2010-02-18 |
Family
ID=38169264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551369A Pending JP2009523806A (ja) | 2006-01-20 | 2007-01-18 | （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070173490A1 (enExample) |
| EP (1) | EP1984342A2 (enExample) |
| JP (1) | JP2009523806A (enExample) |
| AR (1) | AR059095A1 (enExample) |
| CA (1) | CA2637838A1 (enExample) |
| TW (1) | TW200806631A (enExample) |
| WO (1) | WO2007084591A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101541807A (zh) | 2006-09-22 | 2009-09-23 | 詹森药业有限公司 | 用作血管升压素拮抗剂的螺环苯并氮杂 |
| WO2008036755A1 (en) | 2006-09-22 | 2008-03-27 | Janssen Pharmaceutica N.V. | Spiro benzazepines used as vasopressin antagonists |
| US7943782B2 (en) * | 2007-10-19 | 2011-05-17 | Abbott Laboratories | Crystalline chemotherapeutic |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617302A (en) * | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
| US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| US5849780A (en) * | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5686624A (en) * | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5663431A (en) * | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| ATE189121T1 (de) * | 1994-04-22 | 2000-02-15 | Pentech Pharmaceuticals Inc | Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion |
| ATE305454T1 (de) * | 2000-07-05 | 2005-10-15 | Ortho Mcneil Pharm Inc | Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten |
| AU2001296950A1 (en) * | 2000-10-05 | 2002-04-15 | Merck & Co., Inc. | Process for preparation of integrin receptor antagonist intermediates |
| AR044782A1 (es) * | 2003-06-17 | 2005-10-05 | Ortho Pharma Corp | Espirobenzazepinas sustituidas utiles como antagonistas de los receptores de vasopresina |
| HRP20051005A2 (en) * | 2003-06-17 | 2006-09-30 | Janssen Pharmaceutica N.V. | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives |
| JP3972103B2 (ja) * | 2003-09-29 | 2007-09-05 | 国立大学法人 岡山大学 | ピリドピリミジン骨格とステロイド骨格を内蔵する融合化合物及びその製造方法 |
-
2007
- 2007-01-18 CA CA002637838A patent/CA2637838A1/en not_active Abandoned
- 2007-01-18 WO PCT/US2007/001291 patent/WO2007084591A2/en not_active Ceased
- 2007-01-18 EP EP07716746A patent/EP1984342A2/en not_active Withdrawn
- 2007-01-18 US US11/624,292 patent/US20070173490A1/en not_active Abandoned
- 2007-01-18 JP JP2008551369A patent/JP2009523806A/ja active Pending
- 2007-01-19 TW TW096101987A patent/TW200806631A/zh unknown
- 2007-01-19 AR ARP070100245A patent/AR059095A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11208391B2 (en) | Polymorphs and new path to synthesize Tafamidis | |
| US8779161B2 (en) | Asenapine maleate | |
| IL273883B1 (en) | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use | |
| JP2011513485A5 (enExample) | ||
| TW200808735A (en) | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | |
| KR102442536B1 (ko) | 리나글립틴 결정형 및 이의 제조방법 | |
| KR20110002462A (ko) | 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형 | |
| WO2017032673A1 (de) | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff | |
| US8420672B2 (en) | Solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindo1-2-yl)-piperidine-2,6-dione and methods of making the same | |
| UA129159C2 (uk) | ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1 | |
| KR20230121777A (ko) | 화합물의 고체 형태 | |
| JP2010514725A5 (enExample) | ||
| JP2009523806A5 (enExample) | ||
| WO2014049133A1 (en) | New positive allosteric modulators of nicotinic acetylcholine receptor | |
| RS65821B1 (sr) | Derivati 7-fenoksi-n-(3-azabiciklo[3.2.1]oktan-8-il)-6,7-dihidro-5h-pirolo[1,2-b][1,2,4]triazol-2-amina i srodna jedinjenja kao modulatori gama-sekretaze za lečenje alchajmerove bolesti | |
| TWI499584B (zh) | ４－｛３－［順－六氫環戊［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺鹽酸鹽之晶形及其合成方法及含彼之醫藥組合物 | |
| CN106083725A (zh) | 一种高纯度尿囊素的制备方法 | |
| EP1861389B1 (fr) | Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique | |
| JP2022510736A (ja) | 大環状化合物とその使用 | |
| CN116583501A (zh) | 用于治疗与lpa受体活性相关的病症的化合物和组合物 | |
| CA2689377A1 (en) | Amorphous olmesartan medoxomil | |
| CN101622257B (zh) | N-{2-氟-5-[3-(噻吩-2-羰基)-吡唑并[1,5-a]嘧啶-7-基]-苯基}-N-甲基-乙酰胺的多晶型B | |
| WO2014008639A1 (zh) | 制备茚达特罗的方法 | |
| WO2014008640A1 (zh) | 茚达特罗中间体及茚达特罗的合成方法 | |
| TW201402569A (zh) | 具有ｅｐ１受體活性之經取代的三環化合物（一） |